To review the recent recommendation against routinely screening adults for depression in primary care settings by the Canadian Task Force on Preventive Health Care (CTFPHC).
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Clinical Implications
• A new guideline from the CTFPHC recommends that health care professionals do not routinely screen adults for depression in primary care settings.
• There is no evidence from RCTs that depression screening would improve mental health outcomes, but it would consume significant resources and expose some patients to harm.
• Clinicians should be alert to possible symptoms of depression and assess, with referral or management for depression care, as appropriate.
Limitations
• Our article was based on a focused review of the relevant literature, but is not a systematic review.
• As described by the CTFPHC, there are no RCTs that have evaluated depression screening interventions in primary care settings.
M edical screening has been defined as the systematic use of tests to identify asymptomatic people with preclinical disease to prevent or delay the development of advanced disease through early detection and intervention. 1 Since the 1960s, when mammography was first tested in an RCT, enthusiasm for the idea that some diseases can be prevented through early detection has resulted in an explosion in the number of screening tests that have been promoted, some with evidence of benefit and others with little or no such evidence. 2 Some screening interventions lead to reduced morbidity and mortality, but others do not. In fact, screening may not be benign, a point recognized by recent task force recommendations for more restricted use of screening for breast 3, 4 and prostate cancer. 5 In recent years, there has also been greater awareness of the costs of screening, which involve not only the cost of test administration but also costs related to followup assessments to differentiate true-positive and falsepositive screens, consultations with patients with positive screens, treatment, and follow-up services. 1 In cases where screening has not been shown to improve health outcomes, these activities could divert resources away from health services that are known to improve patient health and wellbeing, which is a potentially serious problem. In the United States, for instance, it has been estimated that tests and procedures without proven benefit may account for up to 20% of total health care spending and potentially more. 6 Thus, increasingly, the delivery of appropriate care and the avoidance of interventions without demonstrated benefit has been emphasized as a way to contain costs and reduce risk of harm to patients. 7
The CTFPHC Recommendation
Depression screening, which involves using depression symptom questionnaires to attempt to identify patients who have unrecognized depression, is controversial. 8 It is different from other medical screening programs that seek to find early, asymptomatic disease because it attempts to detect symptoms that are currently experienced by patients, but which have not prompted a diagnosis of depression by a health care professional. In 2002, the USPSTF recommended routine depression screening in primary care settings with staff-assisted depression care programs in place to ensure accurate diagnosis, effective treatment, and follow-up, but not in the absence of such programs. 9 These collaborative care programs typically involve integrated depression care systems with central roles for nonmedical specialists, such as case managers, who work with primary care physicians, mental health specialists, and other providers to provide depression management and followup. 10 In 2005, the CTFPHC issued a similar guideline, 11 based largely on evidence from the systematic review done in conjunction with the 2002 USPSTF guideline, 12, 13 and, in 2009, the USPSTF reiterated its recommendation, 14 based on evidence from 9 RCTs. 15, 16 Recently, the CTFPHC released an updated guideline that departed from its 2005 guideline and from the 2009 USPSTF guideline. The 2013 CTFPHC guideline recommended not routinely screening adults for depression in primary care settings, including patients with average risk of depression and patients who might be expected to be at increased risk. 17 Instead of screening, the CTFPHC encouraged primary care physicians to be alert to possible signs or clinical clues of depression and attend to symptoms of this diagnosis through assessment and, as appropriate, referral or management. 17
Who Is Right and Why Did the CTFPHC Revise Its Previous Recommendation?
No Evidence of Benefit From Depression Screening
There are numerous well-established criteria that should be met before screening is considered. 1, 18 Screening should be considered when a medical condition is important and prevalent, when it cannot be readily detected without screening, when there are accurate and cost-effective screening methods available with a tolerably low rate of false-positive results, and when there are effective treatments. Before a screening program is recommended for implementation, however, there should be evidence from high-quality RCTs of improved health outcomes that justifies the cost and potential adverse effects of screening. In contrast to the 2009 USPSTF systematic review, 15, 16 the systematic review on which the CTFPHC recommendation was based concluded that no RCTs have evaluated the effectiveness of screening for depression. In recommending against screening, the CTFPHC cited this lack of evidence from RCTs and a concern that if routine screening were implemented there would be an excessively high rate of false-positive screening tests. 17 The CTFPHC reported that, in 8 of the 9 RCTs included in the USPSTF review, patients in both the intervention and control groups had been screened so that the main difference between groups was the depression care intervention made available to intervention and control patients, making it impossible to evaluate whether screening itself made a difference. 17 In addition, the CTFPHC noted that in 4 of the 8 trials, a substantial proportion of patients enrolled in the trial were already being treated for depression at the time of enrolment, which did not allow them to assess the ability of screening to improve depression outcomes for patients with previously unidentified depression, which is the purpose of screening. Thus the results of these trials generally suggest that providing resources to ensure guideline-concordant depression care is better than not providing these resources.
However, they do not address the question of whether depression screening benefits patients with previously unrecognized depression.
One additional trial included in the USPSTF systematic review did not provide differential depression treatments to patients in the intervention and control arms of the trial, but was excluded from the CTFPHC review, primarily because patients underwent a diagnostic interview at enrolment and only patients with baseline depression and a random sample of other patients were evaluated at follow-up. In that study, 19 the rate of recognized depression cases was higher in the intervention than control arm of the trial, but the rate of depression treatment and the level of depressive symptoms did not differ between groups.
Potential Barriers to Improving Depression Outcomes by Screening
The CTFPHC determined that there are no clinical trials that have found that patients screened for depression have better depression outcomes than patients who are not screened when the same depression management resources are available to both screened and nonscreened patients. In the absence of evidence of benefit, there are numerous factors that suggest that depression screening, even with collaborative depression care, may not be beneficial to patients.
First, depression screening is done to identify previously unidentified cases of depression, yet over 95% of existing studies on the accuracy of depression screening tools have been conducted with samples that include already diagnosed or treated patients. As a result, these studies likely overestimate the accuracy of these tools for identifying new cases and may substantially exaggerate the yield of new cases that would be identified via screening. 20 Adding to concerns, many studies appear to selectively report diagnostic accuracy results for only cut-off levels that generate high accuracy estimates, neglecting to report results for poor performing cut-offs, even when these cutoffs may be considered standard. This can be seen in the results of a recent meta-analysis on the accuracy of the 9-item PHQ-9, one of the most commonly used depression screening instruments. 21 In that meta-analysis, the estimated sensitivity of the PHQ-9 actually increased as cut-off score severity increased from 7 to 11, which is mathematically impossible if all data are available, but occurred because of selective reporting of results from different cut-off levels in different studies.
Second, the rate of AD use among adults in Canada (7%) is already almost twice the estimated prevalence of MDD (4%), 22 with the great majority prescribed by family physicians. 23 The number of patients who address mental health issues with their physicians may be even larger. Data from Quebec, for instance, show that by 2003 about 20% of adults who consulted a physician received a diagnostic billing code covering a depression or anxiety disorder at some point during the year. 24 A large proportion of Canadians who are treated for MDD do not receive adequate care, 25 but depression screening itself would not improve the quality of care or ensure that patients receive guideline-concordant care.
Third, depression screening would tend to increase identification of depression among people with mild depression who are not obviously depressed enough to seek help or to be otherwise identified. However, the benefits of AD and psychological treatments are substantially less for patients with only mild symptoms of depression, compared with patients with more severe symptoms. [26] [27] [28] [29] [30] [31] Consistent with this, a recent meta-analysis found that psychological treatments were effective for patients referred for treatment by their primary care physician (standardized mean difference = 0.43, 95% CI 0.28 to 0.58), but not for patients recruited into trials via screening (standardized mean difference = 0.13, 95% CI -0.08 to 0.34). 32 Thus, compared with usual care, even guideline concordant care may not benefit many patients with relatively mild depressive symptoms who would likely be identified via screening. 33
The Potential Downside of Depression Screening
The CTFPHC highlighted the risk of false-positive screens and unnecessary treatment, 17 and it has been estimated that only 10% to 20% of positive depression screens would be true-positive screens in primary care settings. 20 Although much research has focused on underdiagnosed and undertreated depression in primary care, the problem of overdiagnosis and overtreatment is increasingly recognized. 34 Indeed, most patients with clinician-identified depression do not meet 12-month criteria for MDD, 34 and, in primary care, the number of false-positive depression diagnoses appears to be larger than the number of missed diagnoses or correctly identified cases. 35 Thus, in the absence of evidence of benefit, routine screening has the potential to expose many patients to avoidable risks. This could include common side effects of ADs (for example, diarrhea, dizziness, dry mouth, fatigue, headache, nausea, sexual dysfunction, excessive sweating, tremors, and weight gain), 36 as well as other less common, but potentially more adverse, effects, such as risk of bleeding and effects on blood pressure and heart rate, as well as drug-drug interactions with other medications. 37 Additionally, the cost of routine depression screening, both in terms of personnel and time, may be significant. Indeed, it has been shown that, even if depression screening were shown to be effective, the cost-effectiveness ratio of screening in primary care would be well beyond what is typically considered acceptable. 38, 39 A study 40 from Quebec found that overall health care costs were about $2000 higher for patients on ADs, with a large proportion of increased costs attributed to patients without a recent history of depression or anxiety. Without demonstrated benefit, depression screening would further burden an already taxed Canadian primary health care system, and choices would have to be made about which necessary services would not be provided or how many fewer patients could be managed to screen for depression.
Conclusion
The CTFPHC should be commended for making the recommendation that physicians in primary care should be alert, but not routinely screen, for depression. Some may believe that the CTFPHC should have simply recommended screening anyway and that the emphasis on the lack of evidence of benefit from screening, without concomitant changes in depression care delivery, is just a technicality. It is important to recognize that depression screening, if implemented without any evidence of benefit, would consume scarce health care resources that could be potentially used to meet other currently unmet health care needs, and would expose some patients to avoidable harms. Further, if screening for depression in primary care were recommended despite the lack of evidence, there may be less incentive to work toward developing effective and feasible mental health care models for primary care settings.
